2017_Fall_CMTA_Report

…Developed stem cell lines from CMT1A patients which will be used to validate promising compounds. MILLION 2.8 CMT1A CMTA-funded researchers have identified promising drug candidates for CMT1A. One of them…

2017_Fall_CMTA_Report

…Developed stem cell lines from CMT1A patients which will be used to validate promising compounds. MILLION 2.8 CMT1A CMTA-funded researchers have identified promising drug candidates for CMT1A. One of them…

CMTAreportSummer2022web

…to you. The CMTA assumes no liability for any information in The CMTA Report. ISSN #1067-0181 Vol. 37, No. 2 Email the CMTA at info@cmtausa.org THE CMTA REPORT | SUMMER…

CMTAreportSummer2022web

…to you. The CMTA assumes no liability for any information in The CMTA Report. ISSN #1067-0181 Vol. 37, No. 2 Email the CMTA at info@cmtausa.org THE CMTA REPORT | SUMMER…

Fall 2024 CMTA Report

…PAGES From CMTA Board Member Steven O’Donnell: cmtausa.org/tin cmtausa.org/pilates cmtausa.org/letsmove FALL 2024 THE CMTA REPORT 1716 THE CMTA REPORT FALL 2024 CMTA’s CRISPR Research Initiative Advances for CMT1A and CMT1B…

Unidentified Type 2 CMT Research

Unidentified Type 2 CMT While researchers have identified more than 90 mutated genes that cause CMT, approximately 50 percent of CMT2 patients do not yet have a definitive genetic diagnosis….

CMTA Adds Science Writer Kenneth Raymond to Team

…author and a CMT advocate committed to raising CMT awareness through fact-based information rooted in the latest understanding of CMT. CMT is a progressive disease of the peripheral nerves that…